Clinical Focus

• Ophthalmology
• Macular and Vitreoretinal Diseases

Administrative Appointments

• Professor and Chairman, Stanford University School of Medicine - Ophthalmology (1997 - present)

Honors and Awards

• Senior Honor Award, American Academy of Ophthalmology (2004)
• Lifetime Achievement Award, American Academy of Ophthalmology (2008)

Professional Education

Graduate & Fellowship Program Affiliations

• Ophthalmology

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Current Research Interests

Clinical Interest and Research
My primary areas of interest are in the diagnosis, medical and surgical treatment of vitreal retinal diseases. These principally include age-related macular degeneration and other diseases of the macula, and tractional syndromes, diabetic retinopathy, and complex forms of retinal detachment. I have been interested in the development of novel technology to diagnose and treat these diseases, including new forms of imaging, laser delivery systems, other microsurgical tools, and new drugs and drug delivery systems that inhibit new blood vessel growth, scarring and intraocular inflammation. I have been actively involved in translational research in the laboratory as well as technology transfer associated with that research for a variety of new therapies that have received FDA clearance and been introduced into clinical practice over the past 30 years.

Administrative and Community Service
I have served on the Board of Directors of a variety of voluntary education and service organizations, including the Corporation of Brown University, multiple scientific advisory boards and various philanthropic and research organizations.

Publications

• Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion. Chan A, Leung LS, Blumenkranz MS. Clin Ophthalmol. 2011: 5 1043-9
• Femtosecond laser capsulotomy. Friedman NJ, Palanker DV, Schuele G, Andersen D, Marcellino G, Seibel BS, Batlle J, Feliz R, Talamo JH, Blumenkranz MS, Culbertson WW. J Cataract Refract Surg. 2011; 37 (7): 1189-98
• Fifty years of ophthalmic laser therapy. Palanker DV, Blumenkranz MS, Marmor MF. Arch Ophthalmol. 2011; 129 (12): 1613-9
• Kinetics of central macular thickness reduction in patients with macular edema after intravitreal drug therapy. He L, Chan A, Leng T, Blumenkranz MS. Clin Ophthalmol. 2011: 5 1751-8
• Longterm cultures of the aged human RPE do not maintain epithelial morphology and high transepithelial resistance. Stanzel BV, Blumenkranz MS, Binder S, Marmor MF. Graefes Arch Clin Exp Ophthalmol. 2011